This application is the U.S. National Stage of International Application No. PCT/DK2013/050054, filed Mar. 5, 2013, which designates the U.S., published in English, and claims priority under 35 U.S.C. §§ 119 or 365(c) to Denmark Application No. PA 2012 70099 filed Mar. 6, 2012.
The present invention relates to a container adapted to dispense its content under pressure. The container of the present invention consists of two separate compartments separated from one another by a slidable piston. The container of the present invention contains a haemostatic paste.
The use of haemostatic agents provides for control of bleeding in surgical procedures. Haemostatic agents, supplement pressure, ligature and other conventional methods of controlling capillary, venous and arterial bleeding are known.
In the field of haemostatic control different devices for application of haemostatic agents are currently on the market.
One such product (Surgiflo®) is a pre-filled syringe applied with an applicator tip. The syringe contains the haemostatic agent in paste form in a volume which allows suitable mixing of the haemostatic agent with any further agent, such as water, saline and thrombin, within the containment unit. Upon manual mixing of the haemostatic agent and the further agent a haemostatic paste is formed within the syringe.
Only after such a haemostatic paste has been formed the user may then apply the paste to the site of bleeding.
The design of the syringe leads to the need for applying manual pressure on the plunger located within the containment unit from behind leading to loss of some control with the direction in which the applicator tip is pointed, i.e. aiming correctly at the site of bleeding is made more difficult.
Due to the viscosity of the haemostatic paste formed in the containment unit after mixing, the user has to apply considerable force to the end of the plunger in order to empty the haemostatic paste out of the containment unit onto a site of bleeding.
Because such a relative high force is needed the precision in applying the product is limited and the device has limited user-friendliness.
Accordingly there is a need for a device in the field of haemostatic control which in one easy-to-use-device provides a haemostatic paste to a site of bleeding directly from a sterile container with great precision and ease for the user.
A vast range of materials are routinely dispensed from pressurized containers. Special containers exists which are able to keep the product out of contact with the propellant. There are generally speaking two types of these containers, “the collapsible bag” type and the “piston” type. The “collapsible bag” type comprises a collapsible bag arrangement where the product is held in a flexible bag secured to the neck of the container with an outlet valve. The propellant is held between the bag and the container wall. Under pressure the bag collapses and extrudes the product from the outlet valve. Filling of the bags is performed under high pressure through the valve which induces phase-separation in paste products. Additionally, filling of the product through the valve makes it possible to have residual paste maintained in the opening of the valve after the filling is completed. This residual paste would function as a plug of paste that would have to be removed prior to the use of the device. Also the opening of the valve is restricted which makes filling and especially emptying of the can difficult
In the “piston” type the container is divided into two chambers by an internal piston, and product and propellant is held separately from each other with this piston. Under pressure of the propellant the piston forces the product from the container through a valve.
The “piston” type containers are usually used for product in liquid, fluid, paste and plastic form, such as foodstuffs (mayonnaise, whipped cream etc.), cosmetics (dentifrice, shaving cream etc.), pharmaceuticals (ointment, rat poison etc.) and chemical products (sealant, adhesive etc.).
The invention relates to a device for dispensing a haemostatic paste from a container under pressure having an interior including a product compartment and a propellant compartment separated from one another and a slidable piston separating the product compartment from the propellant compartment.
This device provides haemostatic paste which may be administered with great precision and by use of a minimal amount of force. Preferably, the haemostatic paste is ready-to-use. In this context “ready-to-use” is intended to mean a paste that can be applied directly from the pressurized container to a subject. This does not exclude the possibility that further ingredients are mixed into the haemostatic paste after it has been expelled from the pressurized container.
In the field of haemostatic control it would be beneficial to be able to provide a haemostatic paste to a site of bleeding directly from a pressurized container with great precision and by use of a minimal amount of force by the user. With haemostatic pastes it is necessary to store the paste separately from the propellant intended to keep the paste under pressure. To do this, the paste is kept separate from the propellant by means of a piston capable of sliding in sealed contact against the interior surface of the body of the container.
In order to obtain the required advantage of the piston, such a system requires that throughout the life of the device, that is from the first use to the last use, the pressure exerted by the propellant must be higher than the vapour pressure of the product.
The invention relates to a device for dispensing a haemostatic paste from a container under pressure.
In this way a sterile and facile administration of haemostatic paste is provided. Surgeons state that the present syringe type applicators require considerable force to apply, which compromises precision. This is overcome by the present invention which makes administration of the haemostatic paste easier by use of a propellant as driving force. The device of the invention is furthermore designed such that it can be pointed in all directions whilst complete emptying of the container is still possible. This is of high importance during a surgical procedure where the bleeding site may be located in difficult to reach places. As stated above previous products typically require considerable manual force for application to a bleeding site and the precise application of the haemostatic agent is difficult and requires some strength of the surgeon.
The device of the present invention comprises a container having an interior including a product compartment and a propellant compartment separated from one another, said container having a first end with a haemostatic paste outlet extending from the product compartment, said outlet being openable and closable. A valve is located in communication with the first end of the product compartment. The valve may be positioned in connection with the haemostatic paste outlet to allow for flow of the haemostatic paste through the haemostatic paste outlet to the exterior of the device. A slidable piston is separating the product compartment from the propellant compartment.
The piston may comprise a primary piston having a primary wall-engaging skirt and a secondary piston having a secondary wall-engaging skirt and between said primary and secondary pistons an interposed deformable sealant material is located.
Under pressure said deformable material may be compressed between the primary and secondary pistons and urged against the container wall to form a seal. To ensure this function the primary piston is preferably in frictional engagement with the wall of the contained and the secondary piston is preferably in loose fit thus to encourage compression of the interposed deformable sealant material. This arrangement of the primary and secondary pistons make it possible to provide an efficient seal between the propellant chamber and the product chamber ensuring that the propellant is not mixed with the product at any time.
The deformable sealant material may be any liquid or semi-solid material which is chemically compatible with the materials it will come into contact with in use. Water-based materials such as aqueous gels of alginic materials are suitable, as are many organic and mineral oils, greases and waxes. The sealant material may in one embodiment be selected from the group consisting of: ethylene glycol, diethylene glycol, butylene glycol, amylene glycol, glycerol, polyglycerin, glycerin, polyvinyl alcohol, silicone, acrylic resin.
In one embodiment the deformable sealant material is a gel. In a more preferred embodiment the deformable sealant is an aqueous gel.
The valve used with the present invention is preferably arranged to allow easy flow of the haemostatic paste through the haemostatic paste outlet and to allow the paste to be dispensed to exit via the valve. As the haemostatic pastes are viscous pastes the valve may be arranged with optimized fluid passage for example by having large inlet and/or out let openings, smooth surfaces and/or a passage way through which the paste may flow without being limited by bends, protrusions etc.
In some advantageous embodiments the valve is furthermore fitted with an exchangeable, bendable and/or cutable long tip of the known type. For example such tips are used in conjunction with Surgiflo® haemostatic paste applicators.
The exchangeable tip can be selected in order to allow administration of the haemostatic paste in hard to reach areas, to allow passage of a fluid with a specific viscosity and/or administer fluid at a specific flow rate.
If a cutable long tip is provided the tip can be cut to a desired length with respect to given circumstances of the administration such as viscosity of fluid (haemostatic paste), administration area etc. If the long tip is at least partly conical the tip can be cut to provide a specific diameter to the exit opening of the tip.
Alternatively a bendable tip is provided which holds its shape after being bent and preferably will not kink when being bend. The bendable tip can be bendable in all directions.
Thus, the user may shape the tip to be optimized for administration of a specific fluid and/or optimized for administration of the fluid in hard to reach areas. For example the exchangeable tip may be bent to have an optimized curvature and a cut to have a desired length by the user.
The tip is in one embodiment between 5-20 cm long, such as 10-20 cm long, such as 15-20 cm long.
In one embodiment the tip is not bendable.
This need for a controlled hold and movement is enhanced when a long tip is use such as the bendable tips mentioned above. This is due to the fact that any movements of the users hands may be enhanced at a distant tip.
Preferably the device comprises a movable actuator coupled to the valving member so that actuating movement of the actuator actuates the valving member to the open position. For example the actuator may be of a form wherein a handle part of the actuator is positioned along the side of the container in a distance and angle from the container making it easy to reach and press by the user preferably with a minimal change of hand position.
Further, the actuator may preferably be arranged to require a minimum of force by the user in order to actuate the valve and administer the haemostatic paste. This can for example be achieved by an actuator arrangement with a hinged lever arm transferring the force applied by the user to the movable valving member. When less force is required to actuate the valve the user is more likely to have a steady hand and is less likely to make any intentional movements with the device ensuring a reliable and optimal administration of the haemostatic paste.
The pressure in the propellant chamber is in one embodiment in the range of 100-500 kPa at room temperature, more preferably in the range of 200-500 kPa, such as 300-500 kPa, more preferably 400-500 kPa. In another embodiment the pressure in the propellant chamber is in the range 100-400 kPa at room temperature, such as 100-300 kPa, more preferably 100-200 kPa.
The propellant may be selected from the group consisting of nitrogen, oxygen, compressed air, butane, propane, chlorofluorocarbon, fluorocarbon and dimethyl ether. In a preferred embodiment the propellant is nitrogen, oxygen or compressed air.
A brief description of the preferred method of filing and assembly of the device is described in Example 1.
The haemostatic paste of the present invention has a viscosity in the range of 700-4.000 Pa·s at room temperature, such as between 1.000-4.000 Pa·s, for example 1.200-4.000 Pa·s, such as 1.400-4.000 Pa·s, for example 1.600-4.000 Pa·s, such as 1.800-4.000 Pa·s, for example 2.000-4.000 Pa·s, such as 2.200-4.000 Pa·s, for example 2.400-4.000 Pa·s, such as 2.600-4.000 Pa·s, for example 2.800-4.000 Pa·s, such as 3.000-4.000 Pa·s, for example 3.200-4.000 Pa·s, such as 3.400-4.000 Pa·s, for example 3.600-4.000 Pa·s, such as 3.800-4000 Pa·s
In another embodiment of the present invention, the haemostatic paste of the present invention has a viscosity in the range 700-4.000 Pa·s, for example 700-3.800 Pa·s, such as 700-3.600 Pa·s, for example 700-3.400 Pa·s, such as 700-3.200 Pa·s, for example 700-3.000 Pa·s, such as 700-2.800 Pa·s, for example 700-2.600 Pa·s, such as 700-2.400 Pa·s, for example 700-2.200 Pa·s, such as 700-2.000 Pa·s, for example 700-1.800 Pa·s, such as 700-1.600 Pa·s, for example 700-1.400 Pa·s, such as 700-1.200 Pa·s, for example 700-1.000 Pa·s, such as 700-900 Pa·s, for example 700-800 Pa·s.
The haemostatic paste of the present invention may comprise 10-25% v/v of gelatine or collagen and a suitable liquid. The suitable liquid may be selected from the group consisting of: sterile water, sterile saline and sterile PBS buffer. The haemostatic paste may be combined with another active ingredient. An appropriate amount of another active agent may be added to the haemostatic paste. Such another active agent may be selected from the group consisting of: germicidal agent, preservative, antimicrobial agents, coagulation factors, antifibrinolytic agents, surfactants, growth factors to promote healing, calcium ions to aid coagulation, adrenaline or other substances capable of constricting blood vessels.
Specific examples of coagulation factors include coagulation factors selected from the group consisting of thrombin, fibrinogen, aprotinin, fibronectin, factor XIII, factor VII, factor VIII, and combinations thereof. Such compounds may be of any mammalian origin, such as of porcine or human origin, or may be obtained by recombinant means by methods well-known to the skilled person. It will be understood that gelatine and collagen are not considered as being coagulation factors.
Antifibrinolytic agents may be selected from the group consisting of tranexamic acid, ε-aminocaproic acid, aprotinin, pepstatin, leupeptin, antipain, chymostatin, gabexate, and mixtures thereof. If present, the antifibrinolytic agent is preferably tranexamic acid.
Antimicrobial agents may be selected from bactericidal or bacteriostatic agents, such as antibiotics and sulphonamides, antiviral compounds, antimycotic agents and anti-infectives.
Surfactants may be selected from the group consisting of anionic surfactants, cationic surfactants, non-ionic surfactants and surface active biological modifiers.
However, in a preferred embodiment of the invention, the composition does not contain such another active agent, i.e. said composition does not contain germicidal agent, coagulation factors, anti-fibrinolytic agents, surfactants, antimicrobial agents, preservative, growth factors, calcium ions, adrenaline and/or other substances capable of constricting blood vessels
All ingredients of the haemostatic paste should be able to tolerate sterilization by radiation and still keep the activity.
Within the device of the present invention, the haemostatic paste preferably has a minimum shelf-life of two years at room temperature.
In use, the valve is opened releasing the internal pressure, the propellant in the propellant chamber expands thereby forcing the secondary piston into even closer contact with the sealant which is urged outward against the container wall. The primary piston advances and extrudes the product from the valve.
It is preferred that the primary and secondary piston is preferably made of a plastic material selected from the group consisting of Polyethylene (HDPE), Polystyrene, Akrylnitril-butadien-styren (ABS), polyamide (PA), Polypropylene, and Poly Vinyl Chloride (PVC). Preferably the primary and secondary piston is made of HDPE.
It is preferred that the container is made of aluminium coated on the inside with a coating. Such a coating may be selected from the group consisting of FDA approved coatings for example, but not limited to PPG2497-303/A (PPG Industries Lackfabrik GmbH), PPG2956-401/A (PPG Industries Lackfabrik GmbH) and J3121 (Valspar).
The valve of the device may be fitted with an appropriate actuator. The pressure needed to be exerted by the user on the actuator in order to empty the device may vary with different actuator types.
The device and all its components are preferably made of materials which can withstand sterilization by gamma radiation or beta radiation. Said sterilization is in one embodiment performed at 10-50 kGy, more preferably at 10-40 kGy, such as 10-30 kGy, more preferably 10-20 kGy. In another embodiment the sterilization is performed at 10-50 kGy, such at 20-50 kGy, more preferably 30-50 kGy, such as 40-50 kGy. In a preferred embodiment the sterilization is performed at 25-30 kGy.
The device of the present invention is preferably completely air and light tight. After having subjected the device to sterilization by radiation the haemostatic paste present in the product chamber is sterile and will remain so until use.
The present disclosure includes a method of providing a haemostatic paste, filling the haemostatic paste into the product compartment through the top of the open container, attaching a valve to the open end of the container, securely sealing the valve to the container by crimping of the valve body around the neck of the container top, filling the propellant compartment under pressure with a suitable propellant through the opening in the propellant compartment, and sealing the propellant compartment by insertion of a plug into the opening in the propellant compartment. The method further provides that the device is sterilised using radiation, preferably wherein the device is filled with haemostatic paste and propellant prior to sterilization. The type of sterilization can be gamma or beta radiation.
In the following the invention is described in further detail with reference to the drawings. However, all drawings are exemplary and are not to be construed as limiting to the invention.
Referring to
Within the container 1 there are, located serially from top to bottom, a primary piston 6, a secondary piston 7 and a membrane partition 8. Located between pistons 6 and 7 there is a mass of deformable sealant material 9. These parts divide the internal volume of the container into a chamber 10 for the haemostatic paste to be dispensed and a chamber 11 for propellant. The presence of the membrane 8 is optional but, when present, it forms with the base 3 a propellant compartment 12. The base 3 has a generally central hole for introduction of propellant during filling after which it is closed by a plug 13.
The crown of the primary piston 6 is shaped to conform generally to the internal configuration of the container top and internal parts of the valve 5 so as to maximise the amount of product which can be expelled by the piston.
The base 3 of the container is domed and has a generally central hole for introduction of propellant during filing after which it is closed by a plug 13. Said hole for filling of propellant can accordingly be opened and closed.
When the force is released by the user, the lever arm 15 and handle 18 will move towards a relaxed state wherein the valve is closed. The movement of the lever handle 18 towards the relaxed position is indicated by arrow R.
When the lever handle 18 is pressed by the user i.e. when the force F is applied by the user to open the valve, the lever handle is brought to a position in which it is parallel to or close to parallel to the longitudinal direction of the container. When the force is relaxed the handle moves back along the direction R. Thus, when the valve is closed the lever handle is relatively close to the container wall and is positioned in an angle which enables the user to easily change grip from holding around the container with all fingers to a grip holding around the lever handle with one or more fingers in order to apply the force F to actuate (i.e. open) the valve and administer the haemostatic paste until the force F is released. The tip 19 shown in
Preparation of the Haemostatic Paste and Filling of the Device.
Cross-linked gelatine powder is mixed with a liquid such that the powder is fully wetted. The paste is filled into the device of the invention through the top of the open container into the product compartment. In this way the product may be filled into the product compartment without the use of valves and without being under pressure. The container is closed by attaching the valve body to the container. The valve is securely sealed to the container by crimping of the valve body. Once the valve is sealed to the container the propellant is filled into the propellant compartment under pressure through the opening in the propellant compartment. The propellant compartment is then sealed by a plug, such as a rubber stopper.
Number | Date | Country | Kind |
---|---|---|---|
PA 2012 70099 | Mar 2012 | DK | national |
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/DK2013/050054 | 3/5/2013 | WO | 00 |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2013/131520 | 9/12/2013 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
2465357 | Correll et al. | Mar 1949 | A |
2465860 | Fleischmann | Mar 1949 | A |
2507244 | Correll | May 1950 | A |
2558395 | Studer | Jun 1951 | A |
2899362 | Sieger et al. | Aug 1959 | A |
3089815 | Kupelwieser et al. | May 1963 | A |
3224434 | Molomut et al. | Dec 1965 | A |
3405712 | Pierick | Oct 1968 | A |
3514518 | Charier-Vadrot | May 1970 | A |
3608593 | McCormick et al. | Sep 1971 | A |
3678933 | Moore et al. | Jul 1972 | A |
3815580 | Oster | Jun 1974 | A |
3869539 | Kring et al. | Mar 1975 | A |
3892876 | Hobday et al. | Jul 1975 | A |
3930052 | De Brou et al. | Dec 1975 | A |
3946732 | Hursham | Mar 1976 | A |
4002173 | Manning et al. | Jan 1977 | A |
4006220 | Gottlieb | Feb 1977 | A |
4013078 | Feild | Mar 1977 | A |
4098728 | Rosenblatt et al. | Jul 1978 | A |
4107288 | Oppenheim et al. | Aug 1978 | A |
4124705 | Rothman et al. | Nov 1978 | A |
4160022 | Delaney et al. | Jul 1979 | A |
4164559 | Miyata et al. | Aug 1979 | A |
4179400 | Tsao et al. | Dec 1979 | A |
4194392 | Lombard et al. | Mar 1980 | A |
4208439 | Hsu | Jun 1980 | A |
4256877 | Karlsson et al. | Mar 1981 | A |
4265233 | Sugitachi et al. | May 1981 | A |
4280954 | Yannas et al. | Jul 1981 | A |
4291013 | Wahlig et al. | Sep 1981 | A |
4292972 | Pawelchak et al. | Oct 1981 | A |
4298598 | Schwarz et al. | Nov 1981 | A |
4300494 | Graiff et al. | Nov 1981 | A |
4320201 | Berg et al. | Mar 1982 | A |
4347234 | Wahlig et al. | Aug 1982 | A |
4362567 | Schwarz et al. | Dec 1982 | A |
4377572 | Schwarz et al. | Mar 1983 | A |
4416813 | Ikeda et al. | Nov 1983 | A |
4424208 | Wallace et al. | Jan 1984 | A |
4453939 | Zimmerman | Jun 1984 | A |
4482386 | Wittwer et al. | Nov 1984 | A |
4492305 | Avery | Jan 1985 | A |
4515637 | Cioca | May 1985 | A |
4522302 | Paikoff | Jun 1985 | A |
4536387 | Sakamoto et al. | Aug 1985 | A |
4540410 | Wood et al. | Sep 1985 | A |
4543332 | Jao et al. | Sep 1985 | A |
4554156 | Fischer | Nov 1985 | A |
4556156 | Frutin | Dec 1985 | A |
4559304 | Kasai et al. | Dec 1985 | A |
4600574 | Lindner et al. | Jul 1986 | A |
4640834 | Eibl et al. | Feb 1987 | A |
4655211 | Sakamoto et al. | Apr 1987 | A |
4685597 | Hirao et al. | Aug 1987 | A |
4696812 | Silbering | Sep 1987 | A |
4702737 | Pizzino | Oct 1987 | A |
4735616 | Eibl et al. | Apr 1988 | A |
4743229 | Chu | May 1988 | A |
4746514 | Warne | May 1988 | A |
4749689 | Miyata et al. | Jun 1988 | A |
4752466 | Saferstein et al. | Jun 1988 | A |
4803075 | Wallace et al. | Feb 1989 | A |
4818517 | Kwee et al. | Apr 1989 | A |
4832686 | Anderson | May 1989 | A |
4837285 | Berg et al. | Jun 1989 | A |
4851521 | Della Valle et al. | Jul 1989 | A |
4861714 | Dean, Jr. et al. | Aug 1989 | A |
4863856 | Dean, Jr. et al. | Sep 1989 | A |
4885161 | Cornell | Dec 1989 | A |
4887743 | Blakesley et al. | Dec 1989 | A |
4891359 | Saferstein et al. | Jan 1990 | A |
4920158 | Murray et al. | Apr 1990 | A |
4925677 | Feijen | May 1990 | A |
4936835 | Haaga et al. | Jun 1990 | A |
4946870 | Partain, III et al. | Aug 1990 | A |
4965203 | Silbering et al. | Oct 1990 | A |
4982769 | Fournier et al. | Jan 1991 | A |
4997753 | Dean, Jr. et al. | Mar 1991 | A |
5007916 | Linsky et al. | Apr 1991 | A |
5017229 | Burns et al. | May 1991 | A |
5023082 | Friedman et al. | Jun 1991 | A |
5024841 | Chu et al. | Jun 1991 | A |
5037740 | Tanaka et al. | Aug 1991 | A |
5041292 | Feijen | Aug 1991 | A |
5061274 | Kensey | Oct 1991 | A |
5061492 | Okada et al. | Oct 1991 | A |
5062834 | Gross et al. | Nov 1991 | A |
5080893 | Goldberg et al. | Jan 1992 | A |
5108421 | Fowler | Apr 1992 | A |
5112750 | Tanaka et al. | May 1992 | A |
5126141 | Henry | Jun 1992 | A |
5129882 | Weldon et al. | Jul 1992 | A |
5134229 | Saferstein et al. | Jul 1992 | A |
5135751 | Henry et al. | Aug 1992 | A |
5135755 | Czech et al. | Aug 1992 | A |
5140016 | Goldberg et al. | Aug 1992 | A |
5149540 | Kunihiro et al. | Sep 1992 | A |
5162430 | Rhee et al. | Nov 1992 | A |
5165938 | Knighton | Nov 1992 | A |
5178883 | Knighton | Jan 1993 | A |
5180583 | Hedner | Jan 1993 | A |
5192300 | Fowler | Mar 1993 | A |
5196185 | Silver et al. | Mar 1993 | A |
5204382 | Wallace et al. | Apr 1993 | A |
5209776 | Bass et al. | May 1993 | A |
5219328 | Morse et al. | Jun 1993 | A |
5275616 | Fowler | Jan 1994 | A |
5281528 | Boctor et al. | Jan 1994 | A |
5292362 | Bass et al. | Mar 1994 | A |
5300494 | Brode, II et al. | Apr 1994 | A |
5304377 | Yamada et al. | Apr 1994 | A |
5306501 | Viegas et al. | Apr 1994 | A |
5324775 | Rhee et al. | Jun 1994 | A |
5328955 | Rhee et al. | Jul 1994 | A |
5330446 | Weldon et al. | Jul 1994 | A |
5350573 | Goldberg et al. | Sep 1994 | A |
5350581 | Kochinke | Sep 1994 | A |
5352715 | Wallace et al. | Oct 1994 | A |
5356614 | Sharma | Oct 1994 | A |
5356883 | Kuo et al. | Oct 1994 | A |
5384333 | Davis et al. | Jan 1995 | A |
5385606 | Kowanko | Jan 1995 | A |
5387208 | Ashton et al. | Feb 1995 | A |
5394886 | Nabai et al. | Mar 1995 | A |
5397704 | Boctor et al. | Mar 1995 | A |
5399361 | Song et al. | Mar 1995 | A |
5401511 | Margalit | Mar 1995 | A |
5418222 | Song et al. | May 1995 | A |
5428022 | Palefsky et al. | Jun 1995 | A |
5428024 | Chu et al. | Jun 1995 | A |
5437672 | Allyne | Aug 1995 | A |
5441491 | Verschoor et al. | Aug 1995 | A |
5443481 | Lee | Aug 1995 | A |
5447966 | Hermes et al. | Sep 1995 | A |
5456693 | Conston et al. | Oct 1995 | A |
5462860 | Mach | Oct 1995 | A |
5478352 | Fowler | Dec 1995 | A |
5503848 | Perbellini et al. | Apr 1996 | A |
5507744 | Tay et al. | Apr 1996 | A |
5510418 | Rhee et al. | Apr 1996 | A |
5512301 | Song et al. | Apr 1996 | A |
5514379 | Weissleder et al. | May 1996 | A |
5516532 | Atala et al. | May 1996 | A |
5520925 | Maser | May 1996 | A |
5531759 | Kensey et al. | Jul 1996 | A |
5540715 | Katsaros et al. | Jul 1996 | A |
5580923 | Yeung et al. | Dec 1996 | A |
5595735 | Saferstein et al. | Jan 1997 | A |
5599735 | Moslehi | Feb 1997 | A |
5614587 | Rhee et al. | Mar 1997 | A |
5618551 | Tardy et al. | Apr 1997 | A |
5643596 | Pruss et al. | Jul 1997 | A |
5645849 | Pruss et al. | Jul 1997 | A |
5648506 | Desai et al. | Jul 1997 | A |
5658592 | Tanihara et al. | Aug 1997 | A |
5660854 | Haynes et al. | Aug 1997 | A |
5667839 | Berg | Sep 1997 | A |
5669934 | Sawyer | Sep 1997 | A |
5672336 | Sharma | Sep 1997 | A |
5674275 | Tang et al. | Oct 1997 | A |
5690675 | Sawyer et al. | Nov 1997 | A |
5690954 | Ilium | Nov 1997 | A |
5698213 | Jamiolkowski et al. | Dec 1997 | A |
5700476 | Rosenthal et al. | Dec 1997 | A |
5712161 | Koezuka et al. | Jan 1998 | A |
5714370 | Eibl et al. | Feb 1998 | A |
5723308 | Mach et al. | Mar 1998 | A |
5743312 | Pfeifer et al. | Apr 1998 | A |
5749895 | Sawyer et al. | May 1998 | A |
5752974 | Rhee et al. | May 1998 | A |
5770229 | Tanihara et al. | Jun 1998 | A |
5791352 | Reich et al. | Aug 1998 | A |
5795330 | Tofighi et al. | Aug 1998 | A |
5798091 | Trevino et al. | Aug 1998 | A |
5823671 | Mitchell et al. | Oct 1998 | A |
5824015 | Sawyer | Oct 1998 | A |
5853749 | Hobbs | Dec 1998 | A |
5856356 | Tsouderos et al. | Jan 1999 | A |
5861043 | Carn | Jan 1999 | A |
5874500 | Rhee et al. | Feb 1999 | A |
5876372 | Grabenkort et al. | Mar 1999 | A |
5883078 | Seelich et al. | Mar 1999 | A |
5890610 | Jansen et al. | Apr 1999 | A |
5895412 | Tucker | Apr 1999 | A |
5902832 | Van Bladel et al. | May 1999 | A |
5908054 | Safabash et al. | Jun 1999 | A |
5931165 | Reich et al. | Aug 1999 | A |
5939259 | Harvey et al. | Aug 1999 | A |
5951531 | Ferdman et al. | Sep 1999 | A |
5951583 | Jensen et al. | Sep 1999 | A |
5957166 | Safabash | Sep 1999 | A |
5959735 | Maris et al. | Sep 1999 | A |
5986168 | Noishiki et al. | Nov 1999 | A |
5997895 | Narotam et al. | Dec 1999 | A |
6007613 | Izoret | Dec 1999 | A |
6096309 | Prior et al. | Jan 2000 | A |
6027741 | Cialdi et al. | Feb 2000 | A |
6042262 | Hajianpour | Mar 2000 | A |
6045570 | Epstein et al. | Apr 2000 | A |
6063061 | Wallace et al. | May 2000 | A |
6066325 | Wallace et al. | May 2000 | A |
6074663 | Delmottet et al. | Jun 2000 | A |
6099952 | Cercone | Aug 2000 | A |
6110484 | Sierra | Aug 2000 | A |
6113948 | Heath | Sep 2000 | A |
6129761 | Hubbell | Oct 2000 | A |
6132759 | Schacht et al. | Oct 2000 | A |
6146587 | Morgan | Nov 2000 | A |
6162241 | Coury et al. | Dec 2000 | A |
6166130 | Rhee et al. | Dec 2000 | A |
6168788 | Wortham | Jan 2001 | B1 |
6171276 | Lippe | Jan 2001 | B1 |
6179872 | Bell et al. | Jan 2001 | B1 |
6193670 | Van Tassel | Feb 2001 | B1 |
6218176 | Berthold et al. | Apr 2001 | B1 |
6224862 | Turecek et al. | May 2001 | B1 |
6261596 | Li et al. | Jul 2001 | B1 |
6277394 | Sierra | Aug 2001 | B1 |
6280727 | Prior et al. | Aug 2001 | B1 |
6283933 | D'Aiessio et al. | Sep 2001 | B1 |
6300128 | Morota et al. | Oct 2001 | B1 |
6303323 | Laskey et al. | Oct 2001 | B1 |
6312474 | Francis et al. | Nov 2001 | B1 |
6312725 | Wallace et al. | Nov 2001 | B1 |
6321951 | Frutin | Nov 2001 | B1 |
6328229 | Duronio et al. | Dec 2001 | B1 |
6334865 | Redmond et al. | Jan 2002 | B1 |
6361551 | Torgerson et al. | Mar 2002 | B1 |
6364519 | Ali | Apr 2002 | B1 |
6387413 | Miyata et al. | May 2002 | B1 |
6391343 | Yen | May 2002 | B1 |
6416739 | Rogerson | Jul 2002 | B1 |
6423037 | Hijikata et al. | Jul 2002 | B1 |
6454787 | Maddalo et al. | Sep 2002 | B1 |
6458380 | Leaderman | Oct 2002 | B1 |
6458386 | Schacht et al. | Oct 2002 | B1 |
6458889 | Trollsas | Oct 2002 | B1 |
6461325 | Delmotte et al. | Oct 2002 | B1 |
6472162 | Coelho | Oct 2002 | B1 |
6495127 | Wallace et al. | Dec 2002 | B1 |
6548081 | Sadozai et al. | Apr 2003 | B2 |
6584858 | Miyazawa et al. | Jul 2003 | B1 |
6620436 | Hughes et al. | Sep 2003 | B1 |
6635272 | Leaderman | Oct 2003 | B2 |
6638538 | Hashimoto et al. | Oct 2003 | B1 |
6649162 | Biering et al. | Nov 2003 | B1 |
6706690 | Reich et al. | Mar 2004 | B2 |
6716435 | Farmer et al. | Apr 2004 | B1 |
6733774 | Stimmeder | May 2004 | B2 |
6831058 | Ikada et al. | Dec 2004 | B1 |
6861046 | Appino et al. | Mar 2005 | B1 |
6887974 | Pathak | May 2005 | B2 |
6902543 | Cherif-Cheikh | Jun 2005 | B1 |
7052713 | Stimmeder | May 2006 | B2 |
7056722 | Coelho | Jun 2006 | B1 |
7109163 | Pendharkar et al. | Sep 2006 | B2 |
7125860 | Renier et al. | Oct 2006 | B1 |
7320962 | Reich et al. | Jan 2008 | B2 |
7393674 | Jiang et al. | Jul 2008 | B2 |
7427607 | Suzuki | Sep 2008 | B2 |
7435425 | Qian et al. | Oct 2008 | B2 |
7547446 | Qian et al. | Jun 2009 | B2 |
7833965 | Pendharkar et al. | Nov 2010 | B2 |
7871637 | Qian et al. | Jan 2011 | B2 |
7927626 | Pendharkar et al. | Apr 2011 | B2 |
7935371 | Williams | May 2011 | B2 |
8071090 | Senderoff et al. | Dec 2011 | B2 |
8119160 | Looney et al. | Feb 2012 | B2 |
8303981 | Wallace et al. | Nov 2012 | B2 |
8329119 | Pearcy et al. | Dec 2012 | B2 |
8357378 | Wallace et al. | Jan 2013 | B2 |
8512729 | Wallace et al. | Aug 2013 | B2 |
8551941 | Pendharkar et al. | Oct 2013 | B2 |
8556848 | Klug et al. | Oct 2013 | B2 |
8603511 | Wallace et al. | Dec 2013 | B2 |
8642831 | Larsen et al. | Feb 2014 | B2 |
8846105 | Koopman et al. | Sep 2014 | B2 |
9265858 | Larsen | Feb 2016 | B2 |
9376674 | Jorquera Nieto et al. | Jun 2016 | B2 |
9408945 | Goessl et al. | Aug 2016 | B2 |
9533069 | Larsen et al. | Jan 2017 | B2 |
9629798 | Senderoff et al. | Apr 2017 | B2 |
9724078 | Larsen et al. | Aug 2017 | B2 |
9999703 | Larsen | Jun 2018 | B2 |
10111980 | Larsen | Oct 2018 | B2 |
10595837 | Larsen et al. | Mar 2020 | B2 |
10653837 | Larsen | May 2020 | B2 |
10799611 | Larsen | Oct 2020 | B2 |
10918796 | Larsen | Feb 2021 | B2 |
20010008636 | Yamamoto et al. | Jul 2001 | A1 |
20010038848 | Donda | Nov 2001 | A1 |
20010041913 | Cragg et al. | Nov 2001 | A1 |
20020006429 | Redmond et al. | Jan 2002 | A1 |
20020010150 | Cortese et al. | Jan 2002 | A1 |
20020010482 | Watt et al. | Jan 2002 | A1 |
20020012982 | Blakesley et al. | Jan 2002 | A1 |
20020015724 | Yang et al. | Feb 2002 | A1 |
20020019062 | Lea et al. | Feb 2002 | A1 |
20020025921 | Petito et al. | Feb 2002 | A1 |
20020026215 | Redmond et al. | Feb 2002 | A1 |
20020027146 | de LaForcade et al. | Mar 2002 | A1 |
20020039594 | Unger | Apr 2002 | A1 |
20020042378 | Reich et al. | Apr 2002 | A1 |
20020061842 | Mansour et al. | May 2002 | A1 |
20020072767 | Zhu | Jun 2002 | A1 |
20020082620 | Lee et al. | Jun 2002 | A1 |
20020111576 | Greene et al. | Aug 2002 | A1 |
20020164322 | Schaufler | Nov 2002 | A1 |
20020173818 | Reever | Nov 2002 | A1 |
20020188196 | Burbank et al. | Dec 2002 | A1 |
20020192271 | Hedner et al. | Dec 2002 | A1 |
20020193448 | Wallace et al. | Dec 2002 | A1 |
20030004449 | Lafratta et al. | Jan 2003 | A1 |
20030008831 | Yang et al. | Jan 2003 | A1 |
20030009194 | Saker et al. | Jan 2003 | A1 |
20030012741 | Furlan et al. | Jan 2003 | A1 |
20030028140 | Greff | Feb 2003 | A1 |
20030032143 | Neff et al. | Feb 2003 | A1 |
20030040701 | Dalmose | Feb 2003 | A1 |
20030064109 | Qian et al. | Apr 2003 | A1 |
20030095993 | Benz et al. | May 2003 | A1 |
20030162708 | Wolff | Aug 2003 | A1 |
20030175410 | Campbell | Sep 2003 | A1 |
20030175419 | Sessa | Sep 2003 | A1 |
20030181659 | Naranda et al. | Sep 2003 | A1 |
20030224056 | Kotha et al. | Dec 2003 | A1 |
20030232746 | Lamberti et al. | Dec 2003 | A1 |
20040062790 | Constantine | Apr 2004 | A1 |
20040076647 | Ferrosan | Apr 2004 | A1 |
20040079763 | Beiring | Apr 2004 | A1 |
20040101546 | Gorman et al. | May 2004 | A1 |
20040120993 | Zhang et al. | Jun 2004 | A1 |
20040186432 | Barry et al. | Sep 2004 | A1 |
20040197388 | Sceusa | Oct 2004 | A1 |
20040214770 | Reich et al. | Oct 2004 | A1 |
20040243043 | McCarthy et al. | Dec 2004 | A1 |
20040267352 | Davidson et al. | Dec 2004 | A1 |
20050008632 | Stimmeder | Jan 2005 | A1 |
20050031691 | McGurk et al. | Feb 2005 | A1 |
20050137512 | Campbell et al. | Jun 2005 | A1 |
20050171001 | Pendharkar et al. | Aug 2005 | A1 |
20050186253 | Lee et al. | Aug 2005 | A1 |
20050214277 | Schaufler | Sep 2005 | A1 |
20050218541 | Peng et al. | Oct 2005 | A1 |
20050239675 | Makansi | Oct 2005 | A1 |
20050245905 | Schmidt et al. | Nov 2005 | A1 |
20050284809 | Looney et al. | Dec 2005 | A1 |
20060002890 | Hersel et al. | Jan 2006 | A1 |
20060002918 | Jiang et al. | Jan 2006 | A1 |
20060052747 | Nishimura et al. | Mar 2006 | A1 |
20060067976 | Ferraro et al. | Mar 2006 | A1 |
20060068013 | DiTizio et al. | Mar 2006 | A1 |
20060115805 | Hansen | Jun 2006 | A1 |
20060121080 | Lye et al. | Jun 2006 | A1 |
20060121104 | Stern | Jun 2006 | A1 |
20060147492 | Hunter et al. | Jul 2006 | A1 |
20060159733 | Pendharkar et al. | Jul 2006 | A1 |
20060167561 | Odar et al. | Jul 2006 | A1 |
20060189516 | Yang et al. | Aug 2006 | A1 |
20060193846 | Stimmeder | Aug 2006 | A1 |
20060204490 | Pendharkar et al. | Sep 2006 | A1 |
20060255053 | Li | Nov 2006 | A1 |
20060282138 | Ota | Dec 2006 | A1 |
20070009578 | Moller | Jan 2007 | A1 |
20070025955 | Lowinger et al. | Feb 2007 | A1 |
20070086958 | Drake et al. | Apr 2007 | A1 |
20070128343 | Chappa | Jun 2007 | A1 |
20070160543 | Moiler | Jul 2007 | A1 |
20070217282 | Lidgren et al. | Sep 2007 | A1 |
20070250007 | Shekalim | Oct 2007 | A1 |
20070264130 | Mallett | Nov 2007 | A1 |
20070264301 | Cleek et al. | Nov 2007 | A1 |
20070264302 | Cleek et al. | Nov 2007 | A1 |
20080029087 | Kidd, III | Feb 2008 | A1 |
20080085316 | Qian et al. | Apr 2008 | A1 |
20080091277 | Deusch et al. | Apr 2008 | A1 |
20080095830 | Van Holten | Apr 2008 | A1 |
20080109002 | Delmotte | May 2008 | A1 |
20080199539 | Baker et al. | Aug 2008 | A1 |
20080286376 | Qian et al. | Nov 2008 | A1 |
20080311172 | Schapira et al. | Dec 2008 | A1 |
20090087569 | Fan et al. | Feb 2009 | A1 |
20090142396 | Odar et al. | Jun 2009 | A1 |
20100028309 | Odar et al. | Feb 2010 | A1 |
20100048758 | Chen et al. | Feb 2010 | A1 |
20100063459 | Preiss-Bloom et al. | Mar 2010 | A1 |
20100113828 | Dalsin | May 2010 | A1 |
20100143447 | Hansen | Jun 2010 | A1 |
20100256671 | Falus | Oct 2010 | A1 |
20100292717 | Petter-Puchner et al. | Nov 2010 | A1 |
20100318048 | Hoeffinghoff et al. | Dec 2010 | A1 |
20110021964 | Larsen | Jan 2011 | A1 |
20110045034 | Nur et al. | Feb 2011 | A1 |
20110059228 | Gillick et al. | Mar 2011 | A1 |
20110270167 | Matusch | Nov 2011 | A1 |
20120128653 | Goessl et al. | May 2012 | A1 |
20120201726 | Pearcy et al. | Aug 2012 | A1 |
20130108671 | McCoy | May 2013 | A1 |
20140220130 | Larsen et al. | Aug 2014 | A1 |
20140369991 | Schutte | Dec 2014 | A1 |
20150037314 | Larsen | Feb 2015 | A1 |
20160120527 | Larsen et al. | May 2016 | A1 |
20160354512 | Larsen | Dec 2016 | A1 |
20170311939 | Larsen et al. | Nov 2017 | A1 |
20180147355 | Larsen | May 2018 | A1 |
20180243468 | Larsen | Aug 2018 | A1 |
20180264194 | Larsen | Sep 2018 | A1 |
20190015546 | Larsen | Jan 2019 | A1 |
20200140625 | Larsen | May 2020 | A1 |
Number | Date | Country |
---|---|---|
0051589 | Jul 1993 | BG |
0099900 | Mar 1997 | BG |
1270240 | Oct 2000 | CN |
3146841 | Jun 1983 | DE |
4119140 | Dec 1992 | DE |
4407875 | Sep 1995 | DE |
0132983 | Feb 1985 | EP |
0156649 | Oct 1985 | EP |
0282316 | Sep 1988 | EP |
0341007 | Nov 1989 | EP |
0341745 | Nov 1989 | EP |
0365705 | May 1990 | EP |
0372966 | Jun 1990 | EP |
0385916 | Sep 1990 | EP |
0395758 | Nov 1990 | EP |
0172710 | Mar 1992 | EP |
0478827 | Apr 1992 | EP |
0493387 | Oct 1993 | EP |
0376931 | Jun 1994 | EP |
0702081 | Mar 1996 | EP |
0737467 | Oct 1996 | EP |
0612252 | May 1999 | EP |
0773740 | Nov 1999 | EP |
1005874 | Jun 2000 | EP |
1022031 | Jul 2000 | EP |
1044693 | Oct 2000 | EP |
1053758 | Nov 2000 | EP |
1084720 | Mar 2001 | EP |
1140235 | Oct 2001 | EP |
1174463 | Jan 2002 | EP |
1258256 | Nov 2002 | EP |
1283063 | Feb 2003 | EP |
0790823 | Jul 2003 | EP |
0891193 | Aug 2003 | EP |
1484070 | Dec 2004 | EP |
1095064 | Jun 2005 | EP |
1543842 | Jun 2005 | EP |
1649867 | Apr 2006 | EP |
1361906 | Apr 2007 | EP |
1414370 | Apr 2007 | EP |
1059957 | Aug 2007 | EP |
1608230 | Jul 2010 | EP |
2 040 724 | Oct 2011 | EP |
2679772 | May 1993 | FR |
2759980 | Aug 1998 | FR |
648619 | Jan 1951 | GB |
697603 | Sep 1953 | GB |
1037937 | Aug 1966 | GB |
1199887 | Jul 1970 | GB |
1584080 | Feb 1981 | GB |
1591654 | Jun 1981 | GB |
2266239 | Oct 1993 | GB |
2393120 | Mar 2004 | GB |
2414021 | Nov 2005 | GB |
51-125156 | Nov 1976 | JP |
59-113889 | Jun 1984 | JP |
60214728 | Oct 1985 | JP |
62070318 | Mar 1987 | JP |
62221357 | Sep 1987 | JP |
01130519 | May 1989 | JP |
05308969 | Nov 1993 | JP |
06254148 | Sep 1994 | JP |
08-024325 | Jan 1996 | JP |
9-504719 | May 1997 | JP |
2004002271 | Jan 2004 | JP |
2004147959 | May 2004 | JP |
2005239713 | Sep 2005 | JP |
2006015144 | Jan 2006 | JP |
2006-296896 | Nov 2006 | JP |
07090241 | Apr 2007 | JP |
2010228932 | Oct 2010 | JP |
2011212182 | Oct 2011 | JP |
910007847 | Oct 1991 | KR |
100751046 | Aug 2007 | KR |
WO 8301244 | Apr 1983 | WO |
WO 8600912 | Feb 1986 | WO |
WO 8902730 | Apr 1989 | WO |
WO 9013320 | Nov 1990 | WO |
WO 9221354 | Dec 1992 | WO |
WO 9222252 | Dec 1992 | WO |
WO 9306802 | Apr 1993 | WO |
WO 9306855 | Apr 1993 | WO |
WO 9310768 | Jun 1993 | WO |
WO 9321908 | Nov 1993 | WO |
WO 9408552 | Apr 1994 | WO |
WO 9417840 | Aug 1994 | WO |
WO 9427630 | Dec 1994 | WO |
WO 9512371 | May 1995 | WO |
WO 9515747 | Jun 1995 | WO |
WO 9525748 | Sep 1995 | WO |
WO 9531955 | Nov 1995 | WO |
WO 9604025 | Feb 1996 | WO |
WO 9606883 | Mar 1996 | WO |
WO 9607472 | Mar 1996 | WO |
WO 9610374 | Apr 1996 | WO |
WO 9610428 | Apr 1996 | WO |
WO 9612447 | May 1996 | WO |
WO 9614368 | May 1996 | WO |
WO 9616643 | Jun 1996 | WO |
WO 9639159 | Dec 1996 | WO |
WO 9640033 | Dec 1996 | WO |
WO 9717023 | May 1997 | WO |
WO 9717024 | May 1997 | WO |
WO 9717025 | May 1997 | WO |
WO 9729792 | Aug 1997 | WO |
WO 9737694 | Oct 1997 | WO |
WO 9808550 | Mar 1998 | WO |
WO 9831403 | Jul 1998 | WO |
WO 9834546 | Aug 1998 | WO |
WO 9836784 | Aug 1998 | WO |
WO 9843092 | Oct 1998 | WO |
WO 9844963 | Oct 1998 | WO |
WO 9851282 | Nov 1998 | WO |
WO 9904828 | Feb 1999 | WO |
WO 9912032 | Mar 1999 | WO |
WO 9913902 | Mar 1999 | WO |
WO 9938606 | Aug 1999 | WO |
WO 9944901 | Sep 1999 | WO |
WO 9945938 | Sep 1999 | WO |
WO 99051208 | Oct 1999 | WO |
WO 009018 | Feb 2000 | WO |
WO 0018301 | Apr 2000 | WO |
WO 0027327 | May 2000 | WO |
WO 0061201 | Oct 2000 | WO |
WO 0074742 | Dec 2000 | WO |
WO 0076533 | Dec 2000 | WO |
WO 0113956 | Mar 2001 | WO |
WO 0128603 | Apr 2001 | WO |
WO 0134206 | May 2001 | WO |
WO 0154735 | Aug 2001 | WO |
WO 0166161 | Sep 2001 | WO |
0197871 | Dec 2001 | WO |
WO 0197826 | Dec 2001 | WO |
WO 0218450 | Mar 2002 | WO |
WO 0222059 | Mar 2002 | WO |
WO 0222184 | Mar 2002 | WO |
WO 0240068 | May 2002 | WO |
WO 02058749 | Aug 2002 | WO |
WO 02064182 | Aug 2002 | WO |
02072128 | Sep 2002 | WO |
WO 02070594 | Sep 2002 | WO |
2002096488 | Dec 2002 | WO |
WO 03007845 | Jan 2003 | WO |
WO 2003004072 | Jan 2003 | WO |
WO 03024426 | Mar 2003 | WO |
WO 03024429 | Mar 2003 | WO |
WO 03055531 | Jul 2003 | WO |
WO 03094983 | Nov 2003 | WO |
WO 04028404 | Apr 2004 | WO |
WO 04028423 | Apr 2004 | WO |
WO 04029095 | Apr 2004 | WO |
WO 04030711 | Apr 2004 | WO |
WO 2004028583 | Apr 2004 | WO |
WO 2004035629 | Apr 2004 | WO |
WO 2004053051 | Jun 2004 | WO |
WO 04075650 | Sep 2004 | WO |
WO 04084869 | Oct 2004 | WO |
WO 04108035 | Dec 2004 | WO |
WO 2004108179 | Dec 2004 | WO |
WO 2004108418 | Dec 2004 | WO |
2005002510 | Jan 2005 | WO |
WO 05000265 | Jan 2005 | WO |
WO 05009225 | Feb 2005 | WO |
WO 05041811 | May 2005 | WO |
WO 05044285 | May 2005 | WO |
WO 05062889 | Jul 2005 | WO |
WO 2005063217 | Jul 2005 | WO |
WO 2005072700 | Aug 2005 | WO |
WO 2005084650 | Sep 2005 | WO |
WO 05107713 | Nov 2005 | WO |
WO 2006005340 | Jan 2006 | WO |
WO 2006031358 | Mar 2006 | WO |
WO 06034568 | Apr 2006 | WO |
WO 06063758 | Jun 2006 | WO |
WO 06128471 | Dec 2006 | WO |
WO 2007001926 | Jan 2007 | WO |
WO 2007018887 | Feb 2007 | WO |
WO 2007092618 | Aug 2007 | WO |
WO 2007133699 | Nov 2007 | WO |
WO 2007137839 | Dec 2007 | WO |
2008019127 | Feb 2008 | WO |
WO 2008016983 | Feb 2008 | WO |
2008060475 | May 2008 | WO |
WO 2008051758 | May 2008 | WO |
WO 2008090555 | Jul 2008 | WO |
WO 2009020612 | Feb 2009 | WO |
WO 2009109194 | Sep 2009 | WO |
WO 2009109963 | Sep 2009 | WO |
WO 2009131752 | Oct 2009 | WO |
WO 2011047753 | Apr 2011 | WO |
WO 2011151384 | Dec 2011 | WO |
WO 2011151386 | Dec 2011 | WO |
WO 2011151400 | Dec 2011 | WO |
WO 2012146655 | Nov 2012 | WO |
WO 2013053753 | Apr 2013 | WO |
WO 2013053755 | Apr 2013 | WO |
WO 2013053759 | Apr 2013 | WO |
WO 2013060770 | May 2013 | WO |
WO 2013185776 | Dec 2013 | WO |
WO 2014086996 | Jun 2014 | WO |
WO 20140202760 | Dec 2014 | WO |
WO 2015086028 | Jun 2015 | WO |
WO 2016058612 | Apr 2016 | WO |
2017005590 | Jan 2017 | WO |
WO 2017098493 | Jun 2017 | WO |
Entry |
---|
FBC Industries Description of Sodium Lactate, accessed on May 31, 2018, http://www.fbcindustries.com/Sodium_Lactate.aspx. |
Office Action for U.S. Appl. No. 14/895,674, titled: “Vacuum Expanded Dry Composition and Syringe for Retaining Same”, dated Feb. 6, 2017. |
Fiss, I., et al., “Use of Gelatin-Thrombin Hemostatic Sealant in Cranial Neurosurgery,” Neurologia Medico-Chirurgica, 47(10):462-467 (2007). |
Mitsuhashi, J., “Invertebrate Tissue Culture Methods,” Springer Lab Manual, p. 407 (2002). |
Oyelese, Yinka, et al., “Postpartum Hemhorrage,” Obstetrics and Gynecology Clinics of North America 34.3, 421-441 (2007). |
Pschyrembel®—Klinisches Wörterbuch, 261st edition, de Gruyter (2007). |
Sigma-Aldrich Datasheet for “Hank's Balanced Salts,” revised Apr. 2007. |
Spotnitz, W. D., et al., “Hemostatus, Sealants, and Adhesives: Components of the Surgical Toolbox,” Transfusion, 48(7):1502-1516 (2008). |
Stief, T. W., “Kallikrein Activates Prothrombin,” Clinical and Applied Thrombosis/Hemostasis, 14.1:97-98 (2008). |
Non-Final Office Action for U.S. Appl. No. 14/516,728 dated Nov. 25, 2014 “Dry Haemostatic Composition”. |
Final Office Action for U.S. Appl. No. 14/136,578, titled: “Device for Promotion of Hemostasis and/or Wound Healing”, dated Feb. 26, 2015 “Dry Haemostatic Composition”. |
Non-Final Office Action for U.S. Appl. No. 14/516,728, titled: “Dry Haemostatic Composition” dated Apr. 14, 2015. |
Non-Final Office Action for U.S. Appl. No. 14/136,578, titled: “Device for Promotion of Hemostasis and/or Wound Healing”, dated Oct. 2, 2014. |
Notice of Allowance for U.S. Appl. No. 14/516,728, titled: “Dry Haemostatic Composition” dated Nov. 27, 2015. |
Final Office Action for U.S. Appl. No. 14/136,578, titled: “Device for Promotion of Hemostasis and/or Wound Healing”, dated Oct. 29, 2015 “Dry Haemostatic Composition”. |
Notice of Allowance for U.S. Appl. No. 14/136,578, titled: “Device for Promotion of Hemostasis and/or Wound Healing” dated Sep. 23, 2016. |
Romanelli, M., et al., “Exudate Management Made Easy”, downloaded from http://www.woundsinternational.com, 6 pgs., (Jan. 29, 2010). |
Chronic Wound Care Guidelines © 2007 http://woundheal.org.documents/final_pocket_guide_treatment.aspx. |
26th Annual Symposium: Clinical Update in Anaesthesiology, Surgery and Perioperative Medicine, Jan. 20-25, 2008. |
Ansell, J., et al., “Gelfoam and Autologous Clot Embolization: Effect on Coagulation,” Investigative Radiology, 13: 115-120 (1978). |
Arai, K., et al., “Clinical Effect of Thrombin-Collagen Sponge Sheet in Surgical Field,” Chiryo (Pharmacology and Treatment), 11(5):413-418 (1983). (English translation of Office Action for Japanese counterpart application 2010-547957, Title: Device for Promotion of Hemostasis and/or Wound Healing, being provided to satisfy “concise explanation” requirement under 37 C.F.R. 1.98(a)(3)). |
Barrow, D.L., et al., “The Use of Greater Omentum Vascularized Free Flaps for Neurosurgical Disorders Requiring Reconstruction”, Journal of Neurosurgery, 60: 305-311 (1984). |
Barton, B., et al., “Fibrin Glue as a Biologic Vascular Patch—A Comparative Study,” Journal of Surgical Research, vol. 40, 1 page; abstract retrieved from http://www.ncbi.nlm.nih.gov on Jan. 3, 2001. (1986). |
Baxter, “GentaFleece Collagen Fleece—Version 5: Instructions for Use—Collagen Sponge with Antibiotic Protection for Surgical Use,” Retrieved from http://www.advancingbiosurgery.com/en_EU/downloads/ifu_gentaflecce.pdf on Mar. 2002, 2 pages. English portion second column of first page. |
Baxter, “Product Catalogue: Collagen,” 4 pages, retrieved from http://www.baxter-ecommerce.com/ecatalog on Feb. 2, 2006 (2006). |
Baxter, “TissuFleece E Package Leaflet,” Baxter International Inc., 4 pages, English portion of instructions for use (2003). |
Baxter, “TissuFleece E, TissuCone E and TissuFoil E: Biomaterials,” Basic scientific Information, 9 pages (2003). |
Boland, T., et al., “Application of Inkjet Printing to Tissue Engineering,” Biotechnol. J., 1:910-917 (2006). |
Boyers, S., et al., “Reduction of Postoperative Pelvic Adhesions in the Rabbit with Gore-Tex Surgical Membrane”, Fertility and Sterility, 49(6,): 1066-1070 (1988). |
Brannon-Peppas, L., et al., “The Equilibrium Swelling Behavior of Porous and Non-Porous Hydrogels,” Absorbent Polymer Technology, Elsevier, Amsterdam, pp. 67-102 (1990). |
Branski, R.C., et al., “Mucosal Wound Healing in a Rabbit Model of Subglottic Stenosis”; Arch Otolaryngol Head Neck Surg, vol. 131, Feb. 2005, p. 153-157. |
Campbell, P.G., et al., “Engineered Spatial Patterns of FGF-2 Immobilized on Fibrin Direct Cell Organization,” Biomaterials, 26: 6762-6770 (2005). |
Campbell, P.G., et al., “Tissue Engineering with the Aid of Inkjet Printers,” Expert Opin. Biol. Ther., 7: 1123-1127 (2007). |
Canal, T., et al., “Correlation Between Mesh Size and Equilibrium Degree of Swelling of Polymeric Networks” Biomedical Materials Research, 23: 1183-1193 (1989). |
Cantor, M.O., et al., “Gelfoam® and Thrombin in treatment of massive gastroduodenal hemorrhage—A preliminary report”, American Journal of Surgery, 883-887 (Dec. 1950). |
Cantor, M.O., et al., “Gelfoam and Thrombin in Gastroduodenal Bleeding: An Experimental Study,” Journal of Laboratory and Clinical Medicine, 35(6): 890-893 (1950). |
Cantor, M.O., et al., “Gelfoam and Thrombin in Treatment of Massive Upper Gastrointestinal Hemorrhage,” American Journal of Surgery, 82(2): 230-235 (Aug. 1951). |
Cascone, M.G., et al., “Collagen and hyaluronic acid based polymeric blends as drug delivery systems for the release of physiological concentrations of growth hormone.” Journal of Materials science: Materials in Medicine; 5: 770-774 (1994). |
Changez, M., et al., Abstract of “Efficacy of antibiotics-loaded interpenetrating network (IPNs) hydrogel based on poly (acrylic acid) and gelatin for treatment of experimental osteomyelitis: in vivo study.”, Biomaterials; 26(14): 2095-2104 (2005). |
Chaplin, J .M., et al., “Use of an Acellular Dermal Allograft for Dural Replacement: An Experimental Study,” Neurosurgery, 45(2): 320-327 (1999). |
Cheung, D., et al., “Mechanism of Crosslinking of Proteins by Glutaraldehyde IV: In Vitro and In Vivo Stability of a Crosslinked Collagen Matrix,” Connective Tissue Research, 25: 27-34 (1990). |
Choi, Y.S., et al., “Studies on Gelatin-Based Sponges. Part III: A Comparative Study of Cross-linked Gelatin/ Alginate, Gelatin/ Hyaluronate and Chitosan/Hyaluronate Sponges and their Application as a wound dressing in fullthickness skin defect of rat.”, J. of Mat. Sci.; Mat. in Med.; 12: 67-73 (Jan. 2001). |
Choi, Y.S., et al., “Studies on gelatin-containing artificial skin: II. Preparation and characterization of cross-linked gelatin-hyaluronate sponge.”, J. Biomed Mater Res., 48: 631-639 (1999). |
Christensen, F, et al., “Qualitative Description of the Wurster-Based Fluid-Bed Coating Process,” Drug Dev and Industry Pharmacy, 23(5): 451-463 (1977). |
Chuang, V.P., et al., “Sheath Needle for Liver Biopsy in High-Risk Patients” Radiology, 166: 261-262 (1988). |
Coenye, K.E., et al., “A Qualitative Morphological comparison of Two Heamostatic Agents in a Porcine Liver Trauma Model,” Surgical Science, 4: 359-364 (2013). |
Collins, D., et al., “Enemata of Gelfoam Milk Suspension Combined with Thrombin-Solution to Control Massive Hemorrhage Following Anorectal Surgery,” The American Journal of Proctology, 2: 60-63 (1951). |
Collins, R., et al., “Use of Collagen Film as a Dural Substitute: Preliminary Animal Studies,” Journal of Biomedical Materials Research, 25: 267-276 (1991). |
De Iaco, P.A., et al., “Efficacy of a Hyaluronan Derivative gel in postsurgical adhesion prevention in the presence of inadequate hemostasis.” Surgery, 130(1): 60-64 (2001). |
De la Torre, R.A., et al., “Hemostasis and Hemostatic agents in minimally invasive surgery”, Surgery, 142(4S): S39-S45 (2007). |
DeLustro, F., et al., “A Comparative Study of the Biologic and Immunologic Response to Medical Devices Derived From Dermal Collagen,” Journal of Biomedical Materials Research, 20: 109-120 (1986). |
Dembo, M.A., et al.; Abstract of “Antiseptic hemostatic preparations, their properties and study”, Lech. Prep. Krovi Tkanei; pp. 139-140 (1974). |
Dodd, G.D., et al., “Minimally invasive treatment of malignant hepatic tumors. At the threshold of a major breakthrough”, Radiographies, 20: 9-27 (2000). |
Drognitz, O., et al., Abstract of “Release of vancomycin and teicoplanin from a plasticized and resorbable gelatin sponge: in vitro investigation of a new antibiotic delivery system with glycopeptides”; lndection Germany (Minich); 34(1): 29-34 (2006). |
Duchene, D., et al., “Pharmaceutical and Medical Aspects of Bioadhesive Systems for Drug Administration,” Drug Dev and Industr Pharmacy, 14(2&3):283-318 (1988). |
Edgerton, M., et al., “Vascular Hamatomas and Hemagiomas: Classification and Treatment,” Southern Medical Journal, 75(12): 1541-1547 (1982). |
Ellegala, D.B., et al., “Use of FloSeal Hemostatic Sealant in Transsphenoidal Pituitary Surgery: Technical Note.”; Neurosurgery, 51: 513-516 (Aug. 2002). |
Filippi, R., et al., “Bovine Pericardium for Duraplasty: Clinical Results in 32 Patients,” Neurological Review, 20:103-107 (2001). |
Flory, P., “Phase Equilibria in Polymer Systems,” Principles of Polymer Chemistry, 13:541-594 (1953). |
“Formulation and Evaluation of Absorbable Gelatin Sponges,” Chapter 3A of Rupali Kale thesis: Design and Development of Surgical Dressings for Advanced Wound Management (2010). |
Fujii, Y., et al., “Safety of GT XIII (Report 2)—Japanese + English translation,” The Clinical Report, 20(17) (Dec. 1986). |
Gall, R.M., “Control of Bleeding in Endoscopic Sinus Surgery: Use of a Novel Gelatin-Based Hemostatic Agent”, Journal of Otolaryngology, 31(5): (2002). |
“Gelfoam Prescribing Information,” Pharmacia & Upjohn (Nov. 1996). |
“Gelfoam® Product Brochure,” Pharmacia & Upjohn (Jun. 2013). |
Gibble, J.W., et al., “Fibrin glue: the perfect operative sealant?” Reviews: Transfusion, 30(8): 741-747 (1990). |
Guinto, F., “Preparation of Gelfoam Particles Using an Orthopedic Rasp,” Radiology, 153: 250 (1984). |
Gurny, R., et al., “Bioadhesive Intraoral Release Systems: Design, Testing and Analysis,” Biomaterials, 5: 336-340 (1984). |
Hae-Won, K., et al., Abstract of “Porus scaffolds of gelatin-hydroxyapatite nanocomposites obtained by biometic approach: Characterization and antibiotic drug release.”; J. of Biomedical Materials Research, 74B(2): 686-698 (2005). |
Harris, W.H., et al., “Topical Hemostatic Agents for Bone Bleeding in Humans,” The Journal of Bone and Joint Surgery, 60-A(4): 454-456 (1978). |
Heller, J., et al., “Release of Norethindrone from Poly(Ortho Esters),” Polymer Engineering and Science, 21: 727-731 (1981). |
Herndon, J., et al., “Compression of the Brain and Spinal Cord Following Use of Gelfoam,” Arch. Surg, 104: 107 (Jan. 1972). |
Hieb, L., et al, “Spontaneous Postoperative Cerebrospinal Fluid Leaks Following Application of Anti-Adhesion Barrier Gel,” Spine, 26(7): 748-751 (2001). |
Hill, et al., “Use of microfibrillar collagen hemostat (avitenet) and thrombin to achieve hemostats after median sternotomy.”; J. Thorac Cardiovasc Surg., 108: 1151-1152 (1994). |
Hill-West, J.L., et al., “Efficiacy of a resorbable hydrogel barrier, oxidized regenerated cellulose and hyaluronic acid in the prevention of ovarian adhesions in a rabbit model.”; Fertility and Sterility, 62(3): 630-634 (1994). |
Hong, S.R., et al., Abstract of “Study on gelatin-containing artificial skin IV: a comparative study on the effect of antibiotic and EGF on cell proliferation during epidermal healing.”; Biomaterials, 22(20): 2777-2783 (2001). |
Hong, Y.M., et al., “The Use of Hemostatic Agents and Sealants in Urology”, The Journal of Urology, 176: 2367-2374 (2006). |
Hood, D., et al., “Efficacy of Topical Hemostat Floseal Matrix in Vascular Surgery,” 24th World Congress of the International Society for Cardiovascular Surgery, Sep. 12-16, 1999, 2 pages. |
Hotz, G., et al., “Collagen and Fibrin as Biologic Binders from Granular Hydroxyapatite,” Deutsche Zeitschrift fur Mund-Kieferund Gesichts-Chirurgie, 13(4): 296-300 (1989). Abstract retrieved from http://www.ncbi.nlm.nih.gov on Jan. 3, 2001. |
International Preliminary Examination Report for International Application No. PCT/DK03/00855, “Gelatine-Based Materials As Swabs”, completed Jun. 2, 2005. |
International Preliminary Report on Patentability (Corrected Version) for International Application No. PCT/DK2005/000063, “Haemostatic Sprays and Compositions”, completed Nov. 6, 2006. |
International Preliminary Report on Patentability for International Application No. PCT/DK2005/000475, “Haemostatic Composition Comprising Hyaluronic Acid”, completed Aug. 16, 2006. |
International Preliminary Report on Patentability for International Application No. PCT/DK2007/050196, “Wound or Tissue Dressing Comprising Lactic Acid Bacteria”, completed May 29, 2009. |
International Preliminary Report on Patentability for International Application No. PCT/DK2009/050048, “Device for Promotion of Hemostasis and/or Wound Healing”, completed Sep. 6, 2010. |
International Preliminary Report on Patentability for International Application No. PCT/DK2013/050054, “Pressurized Container Containing Haemostatic Paste”, dated Sep. 9, 2014. |
International Preliminary Report on Patentability from counterpart International Application No. PCT/DK2011/050082, “A Method for Promotion of Hemostasis and/or Wound Healing”, dated Jul. 6, 2012. |
International Search Report & Written Opinion of the International Searching Authority For International Application No. PCT/DK2007/050196, “Wound or Tissue Dressing Comprising Lactic Acid Bacteria”, dated Apr. 23, 2008. |
International Search Report and Written Opinion of the International Searching Authority from counterpart International Application No. PCT/DK2011/050082, “A Method for Promotion of Hemostasis and/or Wound Healing”, dated Jun. 21, 2011. |
International Search Report for International Application No. PCT/DK2005/000475, “Haemostatic Composition Comprising Hyaluronic Acid”, dated Oct. 25, 2005. |
International Search Report for International Application No. PCT/DK2013/050054, “Pressurized Container Containing Haemostatic Paste”, dated Sep. 10, 2013. |
International Search Report for International Application No. PCT/DK2013/050191, “Dry Haemostatic Composition”, dated Aug. 21, 2013. |
Jeong, B., et al., “Biodegradable Block Copolymers as Injectable Drug-Delivery Systems,” Nature, 388: 860-862 (1997). |
Jonas, R., et al., “A new sealant for knitted Dacron prostheses: Minimally cross-linked gelatin,” Journal of Vascular Surgery, 7(3): 414-419 (1988). |
Katayama, T., et al., “GT XIII safety (3rd report)—Japanese + English translation,” The Clinical Report, vol. 20 (1986). |
Kelly M.J. et al., “The value of an operative wound swab sent in transport medium in the prediction of later clinical wound infection: A controlled clinical and bacteriological evaluation.”, Brit. J. Surgery, 65: 81-88 (1978). |
Kim, K., et al., “Reduction in Leg Pain and Lower-Extremity Weakness with Oxiplex/SP Gel for 1 Year after Laminevtomy, Laminotomy, and Disectomy,” Neurosurgical Focus, 17: 1-6 (2004). |
Kline, D., et al., “Dural Replacement with Resorbable Collagen,” Archives of Surgery, 91: 924-929 (1965). |
Knopp, U., “A New Collagen Foil Versus a Cadaveric Dura Graft for Dural Defects—A Comparative Animal Experimental Study,” European Association of Neurosurgical Societies—Proceedings of the 12th European Congress of Neurosurgery, Lisbon, 17 pages (2003). |
Koçak, I., et al., “Reduction of adhesion formation with cross-linked hyaluronic acid after peritoneal surgery in rats.”, Fertility and Sterility, 72(5): 873-878 (1999). |
Kofidis, T., et al., “Clinically Established Hemostatis Scaffold (Tissue Fleece) as Biomatrix in Tissue and Organ Engineering Research,” Tissue Engineering, 9: 517-523 (2003). |
Kost J., and Langer R., “Equilibrium Swollen Hydrogels in Controlled Release Applications,” Ch. 5: Hydrogels in Medicine and Pharmacy, vol. III: properties and Applications, N. Peppas ed., pp. 95-108 (1987). |
Krill, D., et al., “Topical Thrombin and Powdered Gelfoam: An Efficient Hemostatic Treatment for Surgery,” Journal of Tennessee Dental Association, 66(2): 26-27 (1986). |
Kuhn, J., et al., “Bilateral Subdural Heamatomata and Lumbar Pseudomeningocele Due to a Chronic Leakage of Liquor Cerebrospinalis after a Lumbar Disectomy with the Application of ADCON-L Gel,” Journal of Neurology, Neurosurgery & Psychiatry, 76: 1031-1033 (2005). |
Langer, R., et al., “Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review,” Journal of Macromolecular Science—Reviews in Macromolecular Chemistry and Physics, C23: 61-126 (1983). |
Laquerriere, A., et al., “Experimental Evaluation of Bilayered Human Collagen as a Dural Substitute,” Journal of Neurosurgery, 78: 487-491 (1993). |
Larson, P., “Topical Hemostatic Agents for Dermatologic Surgery,” Journal of Dermatologic Surgery & Oncology, 14: 623-632 (1988). |
Larsson, B., et al., “Surgicel®—an absorbable hemostatic material—in prevention of peritoneal adhesion in rats.”; Acta Chir Scand., 26(144): 375-378 (1978). |
Laurent, C., et al., “Hyaluronic acid reduces connective tissue formation in middle ears filled with absorbable gelatin sponge: An experimental study.”, AM. J. Otolaryngol, 7: 181-186 (1986). |
Le, A., et al., “Unrecognized Durotomy After Lumbar Discectomy: A Report of Four Cases Associated with the Use of ADCON-L,” Spine, 26(1): 115-118 (2001). |
Lee, J., et al., “Experimental Evaluation of Silicone-Coated Dacron and Collagen Fabric-Film Laminate as Dural Substitutes,” Journal of Neurosurgery, 27: 558-564 (1967). |
Lee, P., “Interpretation of Drug-Release Kinetics from Hydrogel Matrices in Terms of Time-Dependent Diffusion Coefficients,” Controlled-Release Technology—Pharmaceutical Applications, Ch. 5, ACS Symposium Series 348, pp. 71-83 (1986). |
Leong, K., et al., “Polyanhydrides for Controlled Release of Bioactive Agents,” Biomaterials, 7: 364-371 (1986). |
Leong, K., et al., “Polymeric Controlled Drug Delivery,” Advanced Drug Delivery Reviews, 1: 199-233 (1987). |
Lewis, K., et al., “Comparison of Two Gelatin and Thrombin Combination Hemostats in a Porcine Liver Abrasion Model,” Journal of Investigative Surgery, 26: 141-148 (2013). |
Li, G., et al., “Evaluation of esterified hyaluronic acid as middle ear-packing material.”, Arch Otolaryngol Head Neck Surg, 127: 534-539 (2001). |
Loeb, J, “The Influence of Electrolytes Upon the Osmotic Pressure of Gelatin Solutions”, J. Biol. Chem., 35: 497-508 (1918). |
Luengo, J., et al., “Prevention of peritoneal adhesions by the combined use of Spongostan and 32% Dextran 70: An experimental study in pigs.” Fertility and Sterility, 29(4): 447-450 (1978). |
Masar, E., et al., “Synthesis of Polyurethanes and Investigation of their Hydrolytic Stability,” Journal of Polymer Science: Polymer Symposium, 66: 259-268 (1979). |
Masuzawa, M., et al., “Experimental Study Related to the Hemostasis Action of GT XIII,” The Clinical Report, 20(2): 471-476 (Feb. 1986). |
Matsumoto, K., et al., “A Gelatin Coated Collagen-Polyglycolic Acid Composite Membrane as a Dural Substitute,” American Society for Artificial Internal Organs Journal, 47: 641-645 (2001). |
Maurer, P, et al., “Vicryl (Polyglactin 910) Mesh as a Dural Substitute,” Journal of Neurosurgery, 63:448-452 (1985). |
Maxson, W.S., et al., “Efficacy of a modified oxidized cellulose fabric in the prevention of adhesion formation.” Gynecol. Obstet. Invest., 26: 160-165 (1988). |
McClure, J., et al., “Massive Gastroduodenal Hemorrhage: Treatment with Powdered Gelfoam and Buffered Thrombin Solution,” Surgery, 32: 630-637 (1952). |
McPherson, J., et al., “An Examination of the Biologic Response to Injectable, Glutaraldehyde Cross-linked Collagen Implants,” Journal of Biomedical Materials Research, 20: 93-107 (1986). |
McPherson, J., et al., “Development and Biochemical Characterization of Injectable Collagen,” J. Dermatol. Surg. Oncol., 12(1): 13-20 (Jul. 7, 1988). |
McPherson, J., et al., “The Effects of Heparin on the Physiochemical Properties of Reconstituted Collagen,” Collagen and Related Research, 1: 65-82 (1988). |
McPherson, J., et al., “The Preparation and Physiochemical Characterization of an Injectable Form of Reconstituted, Glutaraldehyde Crosslinked, Bovine Corium Collagen,” Journal of Biomedical Materials Research, 20: 79-92 (1986). |
Meddings, N., et al., “Collagen Vicryl—A New Dural Prosthesis,” Acta Neurochirurgica, 117: 53-58 (1992). |
Mello, L., et al., “Duraplasty with Biosynthetic Cellulose: An Experimental Study,” Journal of Neurosurgery, 86: 143-150 (1997). |
Miller, D., and Peppas, N., “Diffusional Effects During Albumin Adsorption on Highly Swollen Poly(vinyl Alcohol) Hydrogels,” Eur. Polym. J., 24(7): 611-615 (1988). |
Miller, E.D., et al., “Dose-Dependent Cell Growth in Response to Concentration Modulated Patterns of FGF-2 Printed on Fibrin,” Biomaterials, 27: 2213-2221 (2006). |
Millikan, L., “Treatment of Depressed Cutaneous Scars with Gelatin Matrix Implant: A Multicenter Study,” J. Am. Acad. Dermatol., 16: 1155-1162 (1987). |
Min et al., “Molecular Weight Changes of Sodium Hyaluronate Powder and Solution by Heat treatment,” Matrix Biology Institute, Proceedings of Hyaluronan, Oct. 11-16, 2003. |
Moak, E., “Hemostatic Agents: Adjuncts to Control Bleeding,” Today's O.R. Nurse, pp. 6-10 (1991). |
Mueller, K., “Release and Delayed Release of Water-Soluble Drugs from Polymer Beads with Low Water Swelling,” Controlled-Release Technology—Pharmaceutical Applications, Ch. 11, ACS Symposium Series, 348: 139-157 (1986). |
Narotam, P., et al., “A Clinicopathological Study of Collagen Sponge as a Dural Graft in Neurosurgery,” Journal of Neurosurgery, 82: 406-412 (1995). |
Narotam, P., et al., “Experimental Evaluation of Collagen Sponge as a Dural Graft,” British Journal of Neurosurgery, 7: 635-641 (1993). |
Nimni, M., et al., “Chemically Modified Collagen: A Natural Biomaterial for Tissue Replacement,” Journal of Biomedical Materials Research, 21: 741-771 (1987). |
Nimni, M., Ph.D., “The Cross-Linking and Structure Modification of the Collagen Matrix in the Design of Cardiovascular Prosthesis,” Journal of Cardiac Surgery, 3: 523-533 (1988). |
Nogueira, L., et al., Comparison of gelatine matrix-thrombin sealants used during laparoscopic partial nephrectomy, BJU International, 102: 1670-1674 (2008). |
Novak, D., “Embolization Materials,” Interventional Radiology, pp. 295-313 (1990). |
O'Neill, P., et al., “Use of Porcine Dermis as a Dural Substitute in 72 Patients,” Journal of Neurosurgery, 61: 351-354 (1984). |
Ofner, C.M. and Bubnis, W.A., “Chemical and Swelling Evaluations of Amino Group Crosslinking in Gelatin and Modified Gelatin Matrices,” Pharma. Res., 13: 1821-1827 (1996). |
Oz, M.C., et al., “Controlled clinical trial of a novel hemostatic agent in cardiac surgery.”, Ann Thorac Surg, 69: 1376-1382 (2000). |
Oz, M.C., et al., “Floseal-Matrix: New Generation Topical Hemostatic Sealant”, J. Card. Surg., 18: 486-493 (2003). |
Palm, S., et al., “Dural Closure with Nonpenetrating Clips Prevents Meningoneural Adhesions: An Experimental Study in Dogs,” Neurosurgery, 45(4): 875-882 (1999). |
Parizek, J., et al., “Detailed Evaluation of 2959 Allogeneic and Xenogeneic Dense Connective Tissue Grafts (Fascia Lata, Pericardium, and Dura Mater) Used in the Course of 20 Years for Duraplasty in Neurosurgery,” Acta Neurochirurgica, 139: 827-838 (1997). |
Park, Y-K., et al., “Prevention of Arachnoiditis and Postoperative Tethering of the Spinal Cord with Gore-Tex Surgical Membrane: An Experimental Study with Rats,” Neurosurgery, 42(4): 813-824 (1998). |
Peppas, N. and Barr-Howell, B., “Characterization of the Cross-Linked Structure of Hydrogels,” Ch. 2: Hydrogels in Medicine and Pharmacy, vol. I. Fundamentals, N. Peppas ed., pp. 27-56 (1986). |
Peppas, N. and Brannon-Peppas, L, “Hydrogels at Critical Conditions. Part 1. Thermodynamics and Swelling Behavior,” Journal of Membrane Science, 48: 281-290 (1990). |
Peppas, N. and Khare, A., “Preparation, Structure and diffusional Behavior of Hydrogels in Controlled Release,” Adv. Drug Delivery Reviews, 11: 1-35 (1993). |
Peppas, N. and Korsmeyer, R, “Dynamically Swelling Hydrogels in Controlled Release Applications,” Ch. 6: Hydrogels in Medicine and Pharmacy, vol. III: Properties and Applications, N. Peppas ed., pp. 109-135 (1987). |
Peppas, N. and Lustig, S., “Solute Diffusion in Hydrophilic Network Structures,” Ch. 3: Hydrogels in Medicine and Pharmacy, vol. I: Fundamentals, N. Peppas ed., pp. 57-83 (1986). |
Peppas, N. and Mikos, A., “Preparation Methods and Structure of Hydrogels,” Ch. 1: Hydrogels in Medicine and Pharmacy, vol. I. Fundamentals, N. Peppas ed., pp. 1-25 (1986). |
Peppas, N. and Moynihan, H, “Structure and Physical Properties of Poly(2- Hydroxyethyl Methacrylate) Hydrogels,” Ch. 2: Hydrogels in Medicine and Pharmacy, vol. II: Polymers, N. Peppas ed., pp. 49-64 (1987). |
Peppas, N., “Hydrogels and Drug Delivery,” Current Opinion in Colloid & Interface Science, 2: 531-537 (1997). |
Peppas, N., “Hydrogels in Medicine and Pharmacy,” Hydrogels in Medicine and Pharmacy, vol. 1. Fundamentals, CRC Press, Boca Raton, FL, 180 pages (1986). |
Peppas, N., “Hydrogels in Medicine and Pharmacy,” Hydrogels in Medicine and Pharmacy, vol. 2. Polymers, CRC Press, Boca Raton, FL, 172 pages (1987). |
Peppas, N., “Hydrogels in Medicine and Pharmacy,” Hydrogels in Medicine and Pharmacy, vol. 3. Properties and Applications, CRC Press, Boca Raton, FL, 196 pages (1987). |
Peppas, N., “Hydrogels of Poly (Vinyl Alcohol) and its Copolymers,” Ch. 1: Hydrogels in Medicine and Pharmacy, vol. II: Polymers, N. Peppas ed., pp. 57 pgs (1987). |
Peppas, N., ed., “Other Biomedical Applications of Hydrogels,” Ch. 9: Hydrogels in Medicine and Pharmacy, vol. III: Properties and Applications, pp. 177-186 (1987). |
Pietrucha, K., “New Collagen Implant as Dural Substitute,” Biomaterials, 12: 320-323 (1991). |
Pitt, C., et al., “Biodegradable Drug Delivery Systems Based on Aliphatic Polyesters: Application to Contraceptives and Narcotic Antagonists, ” Controlled Release of Bioactive Materials, R. Baker, ed., (NY: Academic Press) pp. 19-43 (1980). |
Porchet, F., et al., “Inhibition of Epidural Fibrosis with ADCON-L: Effect on Clinical Outcome One Year Following Reoperation for Recurrent Lumbar Radiculopathy,” Neurological Research, 21: 551-560 (1999). |
Product leaflet for FloSeal® Matrix Hemostatic Sealant dated Jul. 2001 (Jul. 2001). |
Purdy, P.D., et al., “Microfibrillar collagen model of canine cerebral infarction”; Strokes, 20(10): 1361-1367 (Oct. 1989). |
Quintavalla, J., et al., “Fluorescently labeled mesenchymal stem cells (MSCs) maintain mutlilineage potential and can be detected following implantation into Particular cartilage defects.”, Biomaterials, 23: 109-119 (2002). |
Raftery, A., “Absorbable haemostatic materials and intraperitoneal adhesion formation.”; Br. J. Surg. 67; 1980; pp. 57-58. |
Ratner, B., “Hydrogel Surfaces,” Ch. 4: Hydrogels in Medicine and Pharmacy, vol. I: Fundamentals, N. Peppas ed., pp. 85-94 (1986). |
Raul, J.S., et al., “Utilisation du Polyester Urethane (NEUROPATCH) Comme Substitut Dural,” Neurochirugie, 49: 83-89, English abstract only on p. 83 (2003). |
Reddy, M., et al., “A Clinical Study of a Fibrinogen-Based Collagen Fleece for Dural repair in Neurosergery,” Acta Neurochirurgica, 144: 265-269 (2002). |
Reese, A.C., “Role of fibronectin in wound healing”, Report date: Sep. 12, 1986; Annual rept. Oct. 1, 1985-Mar. 31, 1986, Final rept. Oct. 1, 1983-Mar. 31, 1986. Corporate Author: Medical Coli of Gerogia Augusta Research Institute. Brunt and Klausner, “Growth factors speed wound healing”, Nature Biotechnology, 6(1): 25-30 (1988). |
Reijnen, M.M.P.J., et al., “Prevention of intra-abdominal abscesses and adhesions using a hyaluronic acid solution in a rat peritonitis model.” Arch Surg. 134: 997-1001 (1999). |
Renkens, K., et al, “A Multicenter, Prospective, Randomized Trial Evaluating a New Hemostatic Agent for Spinal Surgery,” Spine, 26(15): 1645-1650 (2001). |
Riley, S., et al. “Percutaneous Liver Biopsy with Plugging of Needle Track: A Safe Method for Use in Patients with Impaired Coagulation,” Lancet, p. 436 (1984). |
Roda, A., et al., “Protein Microdeposition Using a Conventional Ink-Jet Printer,” BioTechniques, 28(3): 492-496 (2000). |
Rosenblatt, J., et al., “Effect of Electrostatic Forces on the Dynamic Rheological Properties of Injectable Collagen Biomaterials,” Biomaterials, 13: 878-886 (1982). |
Rosenblatt, J., et al., “Injectable Collagen as a pHSensitive Hydrogel,” Biomaterials, 12: 985-995 (1984). |
Ross, J., et al., “Association Between Peridural Scar and Recurrent Radicular Pain After Lumbar Discectomy: Magnetic Resonance Evaluation,” Neurosurgery, pp. 855-863 (1996). |
Rossler, B., et al., “Collagen Microparticles: Preparation and Properties,” Journal of Microencapsulation, 12: 49-57 (1995). |
Sakurabayashi, S., et al., “Clinical evaluation of new hemostatic agent for hemostasis from biopsy wounds in the liver.”; Gastroenterological Endoscopy 30:(10) 29 pgs. (Oct. 1988). |
Sanfilippo, J.S., et al., “Comparison of avitene, topical thrombin and Gelfoam as sole hemostatic agent in tuboplasties.”, Fertility and Sterility, 33(3): 311-316 (1980). |
San-Galli, F., et al., “Experimental Evaluation of a Collagen-Coated Vicryl Mesh as a Dural Substitute,” Neurosurgery, 30: 396-401 (1992). |
Santomaso, A., et al., “Powder flowability and density rations: the impact of granules packing”, Chemical Engineering Science, 58: 2857-2874 (2003). |
Schramm, V., et al., “Gelfoam Paste Injection for Vocal Cord Paralysis,” The Laryngoscope, 88: 1268-73 (1978). |
Shaffrey, C.I., et al., “Neurosurgical Applications of Fibrin Glue: Augmentation of Dural Closure in 134 Patients,” Neurosurgery, 26: 207-210 (1990). |
Shushan, A., et al., “Hyaluronic acid for preventing experimental postoperative intraperitoneal adhesions.”, Journal of Reproductive Medicine, 39(5): 398-402 (1994). |
Shuxian, M. and Zhili, C., “Clinical Observation of the Treatment of Hemoptysis by Ultrasonic Atomizing Inhalation of Thrombin”, Chinese Journal of Critical Care Medicine, 16(2): 30 (1996). |
Sidman, K., et al., “Biodegradable, Implantable Sustained Release Systems Based on Glutamic Acid Copolymers,” Journal of Membrane Science, 7: 227-291 (1979). |
Simamora, P., et al., “Controlled delivery of pilocarpine. 2. In-vivo evaluation of Gelfoam® device,” International Journal of Pharmaceutics, 170(2): 209-214 (1998). |
Smith, A., “New and Nonofficial Remedies: Absorbable Gelatin Sponge—Gelfoam-Upjohn,” Council on Pharmacy and Chemistry, 135(14): p. 921 (1947). |
Smith, K., et al., “Delayed Postoperative Tethering of the Cervical Spinal Cord,” Journal of Neurosurgery, 81: 196-201 (1994). |
Soules , M.R., et al., “The prevention of postoperative pelvic adhesions: An animal study comparing barrier methods with Dextran 70.”, Am. J. Obstet. Gynecol., 143(7): 829-834 (1982). |
Spence et al., “Cerebellar capillary hemangioblastoma: its histogenesis studied by organ culture and electron microscopy.”, Cancer, 35(2): 326-341 (Feb. 1975). |
Springorum, H., “Die Verwendung von Kollagenfolien Zur Uberbruckung von Defekten des Gleitgewebes bei Achillotenotomien und Achillessehnenrupturen,” Akt. Traumatol., 15: 120-121, English abstract only on p. 120 (1985). |
Stricker, A., et al., “Die Verwendung von TissuFoil Membran bei der Sinusbodenaugmentation,” Ellipse, 17: 1-5 (2001). English abstract only on p. 1. |
Sugitachi, A., et al., “A Newly Devised Chemo-Embolic Agent, G.T. XIIIADM,” Gan. To. Kagaku Ryoho, 12: 1942-1943 (1985). English abstract retrieved from http://www.ncbi.nlm.nih.gov on Jan. 2, 2001. |
Sugitachi, A., et al., “Locoregional Therapy in Patients with Malignant Pleural Effusion—Two Different Kinds of ‘BAC Therapy’,” Gan. To. Kagaku Ryoho, 19: 1640-1643 (1992). English abstract retrieved from http://www.ncbi.nlm.nih.gov on Jan. 3, 2001. |
Sugitachi, A., et al., “Preoperative Transcatheter Arterial Chemo-Embolization for Locally Advanced Breast Cancer: Application for New Thrombotic Materials.” Japanese Journal of Surgery, 13: 456-458 (1992). |
Surgiflo® Essential Prescribing Information, Hemostatic Matrix (Made from Absorbable Gelatin Sponge, U.S.P.), 1 page (2005). |
Surgiflo® haemostatic matrix FlexTip, MS0009, 84 pages (2007). |
Surgiflo® Prescription Information, Hemostatic Matrix, (Made from Surgifoam* Absorbable Gelatin Sponge U.S.P.) plus FlexTip, 2 pages (2008). |
Surgiflo® product leaflet, “Surgiflo® Hemostatic Matrix Kit,” 5 pages (2012). |
Surgiflo® product leaflet, “Surgiflo® Hemostatic Matrix,” 12 pages (2009). |
Swann, D.A.,“Studies on hyaluronic acid—I. The preparation and properties of rooster comb hyaluronic acid”, Biochemica et biophysica acta, 156: 17-30 (1968). |
Taheri, Z., “The Use of Gelfoam Paste in Anterior Cervical Fusion,” Journal of Neurosurgery, 34: 438 (1971). |
Tobin, M., et al., “Plugged Liver Biopsy in Patients with Impaired Coagulation,” Digestive Diseases and Science, 34: 13-15 (1989). |
Tucker, H., “Absorbable Gelatin (Gelfoam) Sponge,” Springfield, Illinois, Charles T. Thomas, pp. 3-125 (1965). |
Van den Bosch, E., et al., “Gelatin degradation at elevated temperature”, International Journal of Biological Macromolecules, 32: 129-138 (2003). |
Vandelli, M.A., et al., “The effect of the crosslinking time period upon the drug release and the dynamic swelling of gelatin microspheres,” Pharmazie, 46: 866-869 (1991). |
Vander-Salm, T.J., et al., Abstract of “Reduction of sternal infection by application of topical vancomycin.”, J. of Thoracic and Cardiovascular Surgery, 98(4): 618-622 (1989). |
Verhoeven, A.G., et al., “XV. The use of microporous polymeric powders for controlled release drug delivery systems,” Controlled Drug Delivery. Ch. 15, International Symposium of the Association for Pharmaceutical Technology (APV), Bad Homburg, Nov. 12-14, 1984, pp. 226-237. |
Vinas, F., et al., “Evaluation of Expanded Polytetrafluoroethylene (ePTFE) versus Polydioxanone (PDS) for the Repair of Dura Mater Defects,” Neurological Research, 21: 262-268 (1999). |
Wachoi-Drewek, Z., et al., “Comparative investigation of drug delivery of collagen implants saturated in antibiotic solutions and a sponge containing gentamicin.”, Biomaterials, 17: 1733-1738 (1996). |
Wallace, D., “The Relative Contribution of Electrostatic Interactions to Stabilization of Collagen Fibrils,” Biopolymers, 29: 1015-1026 (1990). |
Wallace, D., et al., “Injectable Cross-Linked Collagen with Improved Flow Properties,” Journal of Biomedical Materials Research, 23: 931-945 (1989). |
Warren, W., et al., “Dural Repair Using Acellular Human Dermis: Experience with 200 Cases: Technique Assessment,” Neurosurgery, 46: 1391-1396 (2000). |
Wassersug, J.D., M.D., “Use of Human Thrombin in Some Cases of Pulmonary Hemorrhage” Pulmonary Hemorrhage, vol. XVII, pp. 354-356 (Mar. 1950). |
Weeks, R., “Microscopy of Soft Materials,” Chapter 1 in Experimental and Computational Techniques in Soft Condensed Matter Physics, Jeffrey Olafsen, Ed, 2010 (2010). |
West et al., “Efficacy of adhesion barriers: Resorbable hydrogel, oxidized regenerated cellulose and hyaluronic acid.”, The Journal of Reproductive Medicine, 41(3) 149-154 (1996). |
Wiesenthal, A.A., et al., Abstract of “New method for packing the external auditory canal, middle ear space, and mastoid cavities after otologic surgery”, The Journal of Otolaryngology; 28(5): 260-265 (1999). |
Wilkinson, H., et al., “Gelfoam Paste in Experimental Laminectomy and Cranial Trephination,” Journal of Neurosurgery, 54: 664-667 (1981). |
Written Opinion of the International Preliminary Examining Authority for counterpart International Application No. PCT/DK2011/050082, “A Method for Promotion of Hemostasis and/or Wound Healing”, dated Mar. 23, 2012. |
Written Opinion of the International Searching Authority (Corrected Version) for International Application No. PCT/DK2005/000063, “Haemostatic Sprays and Compositions”, dated Jul. 26, 2005. |
Written Opinion of the International Searching Authority for International Application No. PCT/DK2005/000475, “Haemostatic Composition Comprising Hyaluronic Acid”, dated Oct. 24, 2005. |
Written Opinion of the International Searching Authority for International Application No. PCT/DK2007/050196, “Wound or Tissue Dressing Comprising Lactic Acid Bacteria”. |
Wu, Y. et al., Abstract of “Design and experimental study of a slow-release antibiotic membrane implant in surgery wound.”, Intern. Des Services de San. Des Forces Armees; 72(7-9): 194-196 (Sep. 1999). |
Xing, Q., et al., “Increasing Mechanical Strength of Gelatin Hydrogels by Divalent Metal Ion Removal”, Sci. Rep., 4: 4706: DOI:10.1038/srep04706(2014). |
Xu, T., et al., “Viability and electrophysiology of neural cell structures generated by the inkjet printing method”, Biomaterials, 27: 3580-3588 (2006). |
Xu, T., et al., “Inkjet Printing of Viable Mammalian Cells,” Biomaterials, 26: 93-99 (2005). |
Yaping, G., “Observation and Nursing of the Treatment of Hemoptysis of Pulmonary Tuberculosis by Ultrasonic Atomizing Inhalation of Thrombin”, Journal of Qilu Nursing, 10(2): 126 (Feb. 2004). |
Youwen, W. et al., “Clinical Observation of the Therapeutic Efficacy of the Treatment of 15 Patients with Hemoptysis by Ultrasonic Atomizing Inhalation of Thrombin”, Chengdu Medical Journal, 30(5): 262 (Oct. 2004). |
Yuki, N., et al., “Effects of Endoscopic Variceal Sclerotherapy Using GT XIII on Blood Coagulation Tests and the Renal Kallikrein-Kinin System,” Gastroentral. Japan, 25: 561-567 (1990). English abstract retrieved from http://www.ncbi.nlm.nih.gov Jan. 2, 2001. |
Ziegelaar, B., et al., “The Characterisation of Human Respiratory Epithelial Cells Cultured on Resorbable Scaffords: First Steps Towards a Tissue Engineered Tracheal Replacement,” Biomaterials, 23: 1425-1438 (2002). |
Ziegelaar, B., et al., “Tissue Engineering of a Tracheal Equivalent, Doctoral Thesis,” Munich, Germany, Ludwig Maximilians University, 2004, 25 pages (2004). |
Zins, M., et al., “US-Guided Percutaneous Liver Biopsy with Plugging of the Needle Track: A Prospective Study in 72 High-Risk Patients,” Radiology, 184: 841-843 (1992). |
Muranyi, A., et al., “Development of gel-forming lyophilized formulation with recombinant human thrombin”, Drug Development and Industrial Pharmacy 41(9): 1566-1573 (2015) (Abstract Only). |
Notice of Allowance for U.S. Appl. No. 14/895,674, titled: “Vacuum Expanded Dry Composition and Syringe for Retaining Same”, dated May 30, 2017. |
Notice of Allowability for U.S. Appl. No. 14/895,674, titled: “Vacuum Expanded Dry Composition and Syringe for Retaining Same”, dated Jun. 12, 2017. |
Notice of Allowance for U.S. Appl. No. 14/980,254, titled: “Dry Haemostatic Composition”, dated Jan. 24, 2018. |
Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority for International Application No. PCT/EP2016/065260, “Syringe for Mixing Two Components and for Retaining a Vacuum in a Storage Condition”, dated Oct. 4, 2016. |
Office Action for U.S. Appl. No. 15/102,994, titled: “Dry Composition Comprising an Extrusion Enhancer”, dated Feb. 22, 2018. |
International Preliminary Report on Patentability for International Application No. PCT/EP2016/065260, “Syringe for Mixing Two Components and for Retaining a Vacuum in a Storage Condition”, date of completion Dec. 6, 2017. |
Notice of Allowability for U.S. Appl. No. 14/980,254, titled: “Dry Haemostatic Composition”, dated Feb. 13, 2018. |
Schreiber, M.A., et al., “Achieving Hemostasis with Topical Hemostats: Making Clinically and Economically Appropriate Decisions in the Surgical and Trauma Settings”, AORN Journal, 94(5): S1-S20 (2011). |
Office Action for U.S. Appl. No. 15/639,237, titled: “Vacuum Expanded Dry Composition and Syringe for Retaining Same”, dated May 8, 2019. |
Notice of Allowance for U.S. Appl. No. 15/534,801, “Syringe for Retaining and Mixing First and Second Substances”, dated Jul. 25, 2019. |
Office Action for U.S. Appl. No. 15/580,181, titled: “Syringe for Mixing Two Components and for Retaining a Vacuum in a Storage Condition”, dated Aug. 23, 2019. |
Notice of Allowance for U.S. Appl. No. 15/639,237, titled: “Vacuum Expanded Dry Composition and Syringe for Retaining Same”, dated Nov. 27, 2019. |
Final Office Action for U.S. Appl. No. 15/580,181, titled: “Syringe for Mixing Two Components and for Retaining a Vacuum in a Storage Condition”, dated Jan. 7, 2020. |
Notice of Allowance for U.S. Appl. No. 15/534,801, titled: “Syringe for Retaining and Mixing First and Second Substances”, dated Jan. 16, 2020. |
Office Action for U.S. Appl. No. 15/513,780, “Dry Composition for Use in Haemostasis and Wound Healing” dated Apr. 9, 2020. |
Office Action for U.S. Appl. No. 15/963,795, titled: “Dry Haemostatic Composition ”, dated Feb. 20, 2020. |
Notice of Allowance for U.S. Appl. No. 15/963,795, titled: “Dry Haemostatic Composition ”, dated Jul. 30, 2020, 2020. |
Final Office Action for U.S. Appl. No. 15/513,780, “Dry Composition for Use in Haemostasis and Wound Healing” dated Oct. 16, 2020. |
Notice of Allowance for U.S. Appl. No. 15/580,181, titled: “Syringe for Mixing Two Components and for Retaining a Vacuum in a Storage Condition”, dated Oct. 1, 2020. |
Office Action for U.S. Appl. No. 16/129,334, “Dry Composition Comprising an Extrusion Enhancer” dated Dec. 17, 2020. |
Notice of Allowance for U.S. Appl. No. 15/513,780 “Dry Composition for Use in Haemostasis and Wound Healing” dated Feb. 23, 2021. |
Number | Date | Country | |
---|---|---|---|
20150045830 A1 | Feb 2015 | US |